Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Reprogramming human T cell function and specificity with non-viral genome targeting.

Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, Chen JW, Schickel JN, Pellerin L, Carmody D, Alkorta-Aranburu G, Del Gaudio D, Matsumoto H, Morell M, Mao Y, Cho M, Quadros RM, Gurumurthy CB, Smith B, Haugwitz M, Hughes SH, Weissman JS, Schumann K, Esensten JH, May AP, Ashworth A, Kupfer GM, Greeley SAW, Bacchetta R, Meffre E, Roncarolo MG, Romberg N, Herold KC, Ribas A, Leonetti MD, Marson A.

Nature. 2018 Jul 11. doi: 10.1038/s41586-018-0326-5. [Epub ahead of print]

PMID:
29995861
2.

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.

Mehta A, Kim YJ, Robert L, Tsoi J, Comin-Anduix B, Berent-Maoz B, Cochran AJ, Economou JS, Tumeh PC, Puig-Saus C, Ribas A.

Cancer Discov. 2018 Jun 13. doi: 10.1158/2159-8290.CD-17-1178. [Epub ahead of print]

PMID:
29899062
3.

Genetic Mechanisms of Immune Evasion in Colorectal Cancer.

Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels MS, Grady WM, Hsu L, Hu-Lieskovan S, Huyghe JR, Kim YJ, Krystofinski P, Leiserson MDM, Montoya DJ, Nadel BB, Pellegrini M, Pritchard CC, Puig-Saus C, Quist EH, Raphael BJ, Salipante SJ, Shin DS, Shinbrot E, Shirts B, Shukla S, Stanford JL, Sun W, Tsoi J, Upfill-Brown A, Wheeler DA, Wu CJ, Yu M, Zaidi SH, Zaretsky JM, Gabriel SB, Lander ES, Garraway LA, Hudson TJ, Fuchs CS, Ribas A, Ogino S, Peters U.

Cancer Discov. 2018 Jun;8(6):730-749. doi: 10.1158/2159-8290.CD-17-1327. Epub 2018 Mar 6.

PMID:
29510987
4.

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A.

N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.

5.

iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy.

Puig-Saus C, Rojas LA, Laborda E, Figueras A, Alba R, Fillat C, Alemany R.

Gene Ther. 2014 Aug;21(8):767-74. doi: 10.1038/gt.2014.52. Epub 2014 Jun 19.

PMID:
24942629
6.

A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology.

Laborda E, Puig-Saus C, Rodriguez-García A, Moreno R, Cascalló M, Pastor J, Alemany R.

Mol Ther. 2014 May;22(5):986-98. doi: 10.1038/mt.2014.7. Epub 2014 Jan 22.

7.

The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.

Puig-Saus C, Laborda E, Rodríguez-García A, Cascalló M, Moreno R, Alemany R.

Cancer Gene Ther. 2014 Feb;21(2):68-73. doi: 10.1038/cgt.2013.85. Epub 2014 Jan 17.

PMID:
24434571
8.

Adeno-associated virus enhances wild-type and oncolytic adenovirus spread.

Laborda E, Puig-Saus C, Cascalló M, Chillón M, Alemany R.

Hum Gene Ther Methods. 2013 Dec;24(6):372-80. doi: 10.1089/hgtb.2013.124. Epub 2013 Oct 8.

9.

Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers.

Puig-Saus C, Gros A, Alemany R, Cascalló M.

Mol Ther. 2012 Jan;20(1):54-62. doi: 10.1038/mt.2011.159. Epub 2011 Aug 23.

Supplemental Content

Loading ...
Support Center